Field Effectiveness of a Typhoid Conjugate Vaccine: The 2018 Navi Mumbai Pediatric TCV Campaign

Kashmira Date Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia;

Search for other papers by Kashmira Date in
Current site
Google Scholar
PubMed
Close
,
Christopher LeBoa Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California;

Search for other papers by Christopher LeBoa in
Current site
Google Scholar
PubMed
Close
,
Seth A. Hoffman Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California;

Search for other papers by Seth A. Hoffman in
Current site
Google Scholar
PubMed
Close
,
Pradeep Haldar Ministry of Health & Family Welfare, Government of India, New Delhi, India;

Search for other papers by Pradeep Haldar in
Current site
Google Scholar
PubMed
Close
,
Pauline Harvey World Health Organization-Country Office for India, National Public Health Surveillance Project, New Delhi, India;

Search for other papers by Pauline Harvey in
Current site
Google Scholar
PubMed
Close
,
Qian An Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia;

Search for other papers by Qian An in
Current site
Google Scholar
PubMed
Close
,
Chenhua Zhang Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia;

Search for other papers by Chenhua Zhang in
Current site
Google Scholar
PubMed
Close
,
Vijay N. Yewale Dr. Yewale Multispecialty Hospital for Children, Navi Mumbai, India;

Search for other papers by Vijay N. Yewale in
Current site
Google Scholar
PubMed
Close
,
Savita Daruwalla Department of Pediatrics, NMMC General Hospital, Navi Mumbai, India;

Search for other papers by Savita Daruwalla in
Current site
Google Scholar
PubMed
Close
,
Dhanya Dharmapalan Dr. Yewale Multispecialty Hospital for Children, Navi Mumbai, India;

Search for other papers by Dhanya Dharmapalan in
Current site
Google Scholar
PubMed
Close
,
Jeetendra Gavhane Department of Pediatrics, MGM New Bombay Hospital, MGM Medical College, Navi Mumbai, India;

Search for other papers by Jeetendra Gavhane in
Current site
Google Scholar
PubMed
Close
,
Shrikrishna Joshi Dr. Joshi’s Central Clinical Microbiology Laboratory, Navi Mumbai, India;

Search for other papers by Shrikrishna Joshi in
Current site
Google Scholar
PubMed
Close
,
Rajesh Rai Department of Pediatrics & Neonatology, Dr. D.Y. Patil Medical College and Hospital, Navi Mumbai, India;

Search for other papers by Rajesh Rai in
Current site
Google Scholar
PubMed
Close
,
Varsha Rathod Rajmata Jijau Hospital, Airoli (NMMC), Navi Mumbai, India;

Search for other papers by Varsha Rathod in
Current site
Google Scholar
PubMed
Close
,
Keertana Shetty Department of Microbiology, Dr. D.Y. Patil Medical College and Hospital, Navi Mumbai, India;

Search for other papers by Keertana Shetty in
Current site
Google Scholar
PubMed
Close
,
Divyalatha S. Warrier Department of Pediatrics, Mathadi Trust Hospital, Navi Mumbai, India;

Search for other papers by Divyalatha S. Warrier in
Current site
Google Scholar
PubMed
Close
,
Shalini Yadav Department of Microbiology, MGM New Bombay Hospital, Navi Mumbai, India;

Search for other papers by Shalini Yadav in
Current site
Google Scholar
PubMed
Close
,
Rahul Shimpi World Health Organization-Country Office for India, National Public Health Surveillance Project, New Delhi, India;

Search for other papers by Rahul Shimpi in
Current site
Google Scholar
PubMed
Close
,
Niniya Jayaprasad World Health Organization-Country Office for India, National Public Health Surveillance Project, New Delhi, India;

Search for other papers by Niniya Jayaprasad in
Current site
Google Scholar
PubMed
Close
,
Lily Horng Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California;

Search for other papers by Lily Horng in
Current site
Google Scholar
PubMed
Close
,
Kirsten Fagerli Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia;

Search for other papers by Kirsten Fagerli in
Current site
Google Scholar
PubMed
Close
,
Priyanka Borhade World Health Organization-Country Office for India, National Public Health Surveillance Project, New Delhi, India;

Search for other papers by Priyanka Borhade in
Current site
Google Scholar
PubMed
Close
,
Debjit Chakraborty National Institute of Cholera and Enteric Diseases, Indian Council of Medical Research, Kolkata, India;

Search for other papers by Debjit Chakraborty in
Current site
Google Scholar
PubMed
Close
,
Arun Katkar World Health Organization-Country Office for India, National Public Health Surveillance Project, New Delhi, India;

Search for other papers by Arun Katkar in
Current site
Google Scholar
PubMed
Close
,
Abhishek Kunwar World Health Organization-Country Office for India, National Public Health Surveillance Project, New Delhi, India;

Search for other papers by Abhishek Kunwar in
Current site
Google Scholar
PubMed
Close
,
Jason R. Andrews Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California;

Search for other papers by Jason R. Andrews in
Current site
Google Scholar
PubMed
Close
,
Sunil Bahl World Health Organization South-East Asia Regional Office, New Delhi, India

Search for other papers by Sunil Bahl in
Current site
Google Scholar
PubMed
Close
,
Pankaj Bhatnagar World Health Organization-Country Office for India, National Public Health Surveillance Project, New Delhi, India;

Search for other papers by Pankaj Bhatnagar in
Current site
Google Scholar
PubMed
Close
,
Shanta Dutta National Institute of Cholera and Enteric Diseases, Indian Council of Medical Research, Kolkata, India;

Search for other papers by Shanta Dutta in
Current site
Google Scholar
PubMed
Close
, and
Stephen P. Luby Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California;

Search for other papers by Stephen P. Luby in
Current site
Google Scholar
PubMed
Close

ABSTRACT.

Typbar-TCV®, a typhoid conjugate vaccine (TCV), was prequalified by the World Health Organization in 2017. We evaluated its effectiveness in a mass vaccination program targeting children 9 months to 14 years in Navi Mumbai, India, from September 2018 to July 2020. We compared laboratory-confirmed typhoid cases from six clinical sites with age-matched community controls. Of 38 cases, three (8.6%) received TCV through the campaign, compared with 53 (37%) of 140 controls. The adjusted odds ratio of typhoid fever among vaccinated children was 0.16 (95% CI: 0.05–0.55), equivalent to a vaccine effectiveness of 83.7% (95% CI: 45.0–95.3). Vaccine effectiveness of Typbar-TCV in this large public sector vaccine introduction was similar to prior randomized controlled trials, providing reassurance to policymakers that TCV effectiveness is robust in a large-scale implementation.

INTRODUCTION

Salmonella enterica subspecies enterica serovar Typhi (S. Typhi), the causative agent of typhoid fever, caused an estimated 11 million infections and 116,800 deaths worldwide in 2017, with children experiencing the greatest burden of disease.1 Typhoid is fecal-orally transmitted and South Asia and sub-Saharan Africa have the highest global incidence.2 Alongside typhoid vaccination, the WHO recommends water, sanitation, and hygiene (WASH) interventions, but these require longer term investment and government implementation to accomplish.35 The emergence of multidrug-resistant and extensively drug-resistant lineages have increased the need for more immediate preventive measures.6

Typhoid vaccines have existed for decades, including an oral live attenuated vaccine, Ty21a, and an injectable Vi capsular polysaccharide (ViPS) vaccine, but they are not licensed for children <2 years old, the Ty21a vaccine requires multiple doses, and the ViPS vaccine requires revaccination every 3 years.3 Typhoid conjugate vaccines (TCVs), two of which the WHO has prequalified, are highly immunogenic, can be administered to infants, and can potentially offer a longer duration of protection (estimated >7 years).3,7 One of these, Typbar-TCV® (Bharat Biotech International Limited, Hyderabad, India), is a single-dose TCV containing the S. Typhi Vi capsular polysaccharide antigen conjugated to tetanus toxoid carrier protein.8 Multiple randomized controlled trials in endemic regions have found this vaccine to have substantial vaccine efficacy, including in Nepal (79.0%, 95% CI: 61.9–88.5), Bangladesh (85.0%, 97.5% CI: 76.0–91.0), and Malawi (80.7%, 95% CI: 64.2–89.6).911

Navi Mumbai is an urban municipality administered by the Navi Mumbai Municipal Corporation (NMMC), known to have a high burden of typhoid among children, including multidrug-resistant strains.12,13 Health services in NMMC are provided through 22 urban health posts that each serve defined sections of the city. In 2018, the NMMC planned the first phase of a pediatric vaccination campaign using Typbar-TCV®, 14 and approximately 113,420 children between 9 months and 14 years old received TCV.14 A second round of vaccination was planned for 2020 but was delayed indefinitely due to the COVID-19 pandemic. The study design included a population-based community health survey to monitor for cases and to gather participant demographic and healthcare utilization measurements. The survey included information on demographic and socioeconomic characteristics, healthcare use and hospitalization information, receipt of typhoid vaccine, history of other childhood immunizations, household wealth, and potential risk factors for typhoid. Study staff requested vaccination cards from participants who reported typhoid vaccine receipt. All data were collected using CommCare on password-protected tablets. The survey was initiated after the vaccination campaign and was ongoing between September 2018 and March 2020.15

To gain a better understanding of the field vaccine effectiveness of Typbar-TCV, we performed a case–control analysis in vaccine-eligible children after the first vaccination campaign phase. Cases were NMMC residents between 9 months to 14 years of age at the start of the vaccination campaign (July 2018) who received a positive S. Typhi blood culture between September 2018 and March 2020 at one of six surveillance sites.14,15 Cases were each matched up to four controls (matchit function from R “MatchIt” package, R version 4.0.4), who were enrolled from the population-based community assessment survey. Controls were considered eligible if they 1) had not experienced fever within 30 days and 2) were between 9 months and 14 years old on July 1, 2018. Controls were matched to cases by 1) date of survey (within 14 days from case enrollment) and 2) age at time of TCV vaccination (within 12 months of case). Study staff collected data from both cases and controls using a structured questionnaire administered to a parent/guardian (embedded within the population-based community health survey). Case surveys were performed after a positive blood culture was confirmed.

A child was defined as vaccinated if a respondent presented a TCV campaign vaccination card or recalled that the child received a TCV vaccine during the vaccination campaign (“TCV Card or Campaign Recall”). We estimated sample sizes based on vaccine effectiveness of 85% (i.e., odds ratio = 0.15).911 Assuming an average of three controls per case, for a range of laboratory-confirmed cases and at different levels of TCV coverage among controls (40%, 50%, 60%, 70%, and 80%) we assumed we could estimate effectiveness with reasonable precision (95% CI band of less than ± 20% effectiveness 0.20).16

We used conditional logistic regression to calculate the odds ratio of TCV vaccination between matched cases and controls (clogit function from R “survival” package, R version 4.0.4). We additionally conducted a subanalysis using a more lenient definition of vaccinated by including those who recalled being vaccinated with TCV at any point in time (“TCV Card or recall at any time”). We excluded cases and potential controls who refused or reported not knowing the answer to the vaccination question. We also conducted stratified analyses by age (under 5 years and 5–14 years at the time of campaign). We attempted an age-stratified analysis for those under 2 years, but the model did not converge due to the limited sample size. All code used for the analysis can be found on Github (https://github.com/chrisleboa/india_typhoid/tree/master/Vaccine%20Case%20Control%20Analysis). Because typhoid was rare in this population during the surveillance period, we assumed that the odds ratio was a reasonable estimate of the relative risk.17 We estimated vaccine effectiveness using the formula: (1 – conditional odds ratio of cases being vaccinated) × 100.18

We obtained parental/guardian written informed consent for all study participants. The evaluation protocol was approved by the Institutional Ethics Committee, Indian Council of Medical Research—National Institute of Cholera and Enteric Diseases (No. A-1/2020-IEC); WHO Research Ethics Review Committee (ERC.0002923); Centers for Disease Control and Prevention Institutional Review Board (#7026); Stanford University Institutional Review Board (IRB-39627); and institutional review committees of all evaluation sites.

A total of 38 participants had blood culture–confirmed typhoid and documented TCV vaccination status according to our primary definition. Thirty-five cases were age- and enrollment time–matched to 140 corresponding controls during the study period (September 2018–March 2020) (Figure 1). Cases and matched controls had similar demographic characteristics and household WASH components (Table 1). Most participants reported improved sanitation facilities, including flush toilets in their home, and an improved water source (Table 1).

Figure 1.
Figure 1.

Flow chart of study design. TCV = typhoid conjugate vaccine.

Citation: The American Journal of Tropical Medicine and Hygiene 111, 4; 10.4269/ajtmh.24-0181

Table 1

Demographic characteristics of respondent/head of household, eligible child, and household water source and sanitation information

Variable Matched Cases (N = 35) Controls (N = 140) P-Value
Demographic characteristics of respondent or head of household
 Female sex (n, %) 28 (80) 111 (79) 1.00
 Age 30 − 39 years (n, %) 22 (63) 71 (51) 0.27
 Nonprofessional occupation (n, %)* 34 (96) 130 (93) 0.66
 Middle school or lower education (n, %) 25 (71) 71 (51) 0.04
Demographic characteristics of eligible child
 Female sex (n, %) 12 (34) 69 (49) 0.16
 Age under 5 years (n, %) 8 (23) 33 (23) 1.00
Household characteristics
 Three- to four-person household (n, %) 20 (57) 72 (51) 0.68
 Improved water source (n, %) 35 (100) 139 (99) 1.00
 Flush toilet (n, %) 29 (83) 122 (87) 0.81
 No. who share toilet with people outside their family (n, %) 5 (14) 17 (12) 0.99
 Handwashing facility (n, %)§ 35 (100) 131 (94) 0.30
 Electricity in home (n, %) 35 (100) 139 (99) 1.00

Nonprofessional occupation includes unskilled workers, trade workers, and skilled workers.

Middle school or lower education includes no formal education through Grade 10.

Improved water source is defined as piped into dwelling, yard, or plot; public tap or standpipe; tube well or borehole; protected well; or protected spring.

Handwashing facility is defined as a place in the home or right outside the home where one is able to wash hands.

Of participants with laboratory-confirmed typhoid, 8.6% (3/35) received Typbar TCV during the campaign, compared with 38.0% (53/176) of control participants (Table 2). The conditional odds ratio of being vaccinated in the case group versus the control group was 0.16 (95% CI: 0.05–0.55). The estimated vaccine effectiveness was 83.7% (95% CI: 45.0–95.3). Our analysis of the alternative vaccination definition (expanding recall outside of campaign) decreased the estimated effectiveness of the vaccine (Table 2).

Table 2

TCV vaccination rates among cases and controls, and modeled estimates of vaccine effectiveness by vaccinated definition and age

Vaccinated Definition or Age Typhoid Cases No. of Typhoid Cases Vaccinated (%) Matched Controls No. of Typhoid Controls Vaccinated (%) Modeled Vaccine Effectiveness (95% CI)
TCV card or campaign recall 35 3 (8.6) 140 53 (38.0) 83.7% (45.0–95.3)
TCV card or recall at any time 34 7 (20.0) 136 58 (43.0) 62.8% (10.7–84.5)
Age <5 years 8 1 (12.5) 33 11 (33.0) 72.3% (–144.0 to 96.9)
Age 5–14 years 27 2 (7.4) 107 42 (39.0) 87.0% (42.9–97.1)

TCV = typhoid conjugate vaccine.

We found a numerically lower effectiveness among those under 5 years (72.3%, 95% CI: –144.0–96.9) compared with children 5 to 14 years of age (87.0%, 95% CI: 42.9–97.1) (Table 2), but CIs were wide, and we were not powered to compare effectiveness between age groups. However, these findings mirror age-based TCV efficacy published in Malawi, in which efficacy was 74.4% (95% CI: 31.7–90.4) in children under 5 years at the time of vaccination compared with 83.7% (95% CI: 63.6–92.7) in older children.11 We did not enroll enough children under 2 years with typhoid to estimate the impact of TCV vaccination amongst this age group, but work from a phase 3 trial in Bangladesh suggests that TCV is highly protective among children under 2 years (81.0%, 95% CI: 39.0–94.0).10

The vaccine effectiveness described in this study (83.7%) is similar to the efficacy demonstrated in recent TCV clinical trials, which range from 80% to 85%.911 Our study did find three blood culture–confirmed cases of typhoid among TCV-vaccinated individuals. Of note, other TCV randomized controlled trials experienced typhoid infection in vaccine arms.9,10 The continued incidence of typhoid among those vaccinated suggests a need for additional measures, such as water and sanitation infrastructure, to potentially eliminate typhoid in endemic areas.5,15

This study was limited by self-report of vaccination status, which may have led to recall bias, potentially underestimating or overestimating the true proportion of vaccinated individuals; of note, Typbar-TCV has been available in India for private sector purchase since 2013.19 Additionally, the COVID-19 pandemic altered healthcare-seeking behavior and cut short our planned data collection activities. We anticipated enrolling more cases and controls, but enrollment was short of expectations, which may be due to the low sensitivity of even optimally collected blood cultures for typhoid fever diagnosis.20 More research is needed to understand who was reached and missed in mass vaccination campaigns like this one and to assess the long-term impact of TCV vaccination on population-level incidence of typhoid.

This field effectiveness evaluation of Typbar-TCV provides critical data needed for local, national, and global TCV decision-making and development of policies to reduce the burden of typhoid. Typbar-TCV had comparable vaccine effectiveness in Navi Mumbai as in other trials, and the programmatic effect of this public-sector campaign was consistent with the estimated vaccine coverage.15 These results provide reassuring evidence that vaccine introduction is scalable and should enable increased availability and access to TCVs in typhoid-endemic countries.

ACKNOWLEDGMENTS

We thank the following organizations and individuals for their contributions to this study: the Navi Mumbai Municipal Corporation leadership and staff, the Government of India Ministry of Health and Family Welfare Universal Immunization Program, State of Maharashtra Department of Public Health and Family Welfare, Indian Academy of Pediatrics Navi Mumbai Chapter, Bharat Biotech International Limited, the Indian Council of Medical Research, WHO India National Public Health Surveillance Project, Grant Government Medical College (Dr. Nilma Hirani), and the Centers for Disease Control and Prevention, Atlanta, GA (Dr. Kathleen Wannemuehler, Benjamin Nygren, and Matt Mikoleit). We thank medical writer Marian Blazes for her support as the author of the first draft of this manuscript.

REFERENCES

  • 1.

    GBD 2017 Typhoid and Paratyphoid Collaborators , 2019. The global burden of typhoid and paratyphoid fevers: A systematic analysis for the global burden of disease study 2017. Lancet Infect Dis 19: 369381.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Mogasale VV , Ramani E , Mogasale V , Park JY , Wierzba TF , 2018. Estimating typhoid fever risk associated with lack of access to safe water: A systematic literature review. J Environ Public Health 2018: 9589208.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    World Health Organization , 2019. Typhoid vaccines: WHO position paper, March 2018—Recommendations. Vaccine 37: 214216.

  • 4.

    Tseng KK , Joshi J , Shrivastava S , Klein E , 2020. Estimating the cost of interventions to improve water, sanitation and hygiene in healthcare facilities across India. BMJ Glob Health 5: e003045.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Kim C , Goucher GR , Tadesse BT , Lee W , Abbas K , Kim JH , 2023. Associations of water, sanitation, and hygiene with typhoid fever in case-control studies: A systematic review and meta-analysis. BMC Infect Dis 23: 562.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Qamar FN et al., 2020. Antimicrobial resistance in typhoidal Salmonella: Surveillance for enteric fever in Asia project, 2016–2019. Clin Infect Dis 71: S276S284.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Birkhold M , Mwisongo A , Pollard AJ , Neuzil KM , 2021. Typhoid conjugate vaccines: Advancing the research and public health agendas. J Infect Dis 224: S781s787.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Mohan VK , Varanasi V , Singh A , Pasetti MF , Levine MM , Venkatesan R , Ella KM , 2015. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: A multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clin Infect Dis 61: 393402.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Shakya M et al., 2021. Efficacy of typhoid conjugate vaccine in Nepal: Final results of a phase 3, randomised, controlled trial. Lancet Glob Health 9: e1561e1568.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Qadri F et al., 2021. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: A cluster-randomised trial. Lancet 398: 675684.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Patel PD et al., 2021. Safety and efficacy of a typhoid conjugate vaccine in Malawian children. N Engl J Med 385: 11041115.

  • 12.

    Gavhane J , Yewale V , Weekey P , Dhanya , Warrior D , 2010. Enteric fever in children from Navi Mumbai—Clinical profile, hematological features, sensitivity patterns and response to antimicrobials. Pediatr Infect Dis 2: 59.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Jayaprasad N , Borhade P , LeBoa C , Date K , Joshi S , Shimpi R , Andrews JR , Luby SP , Hoffman SA , 2023. Retrospective review of blood culture-confirmed cases of enteric fever in Navi Mumbai, India: 2014–2018. Am J Trop Med Hyg 109: 571574.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Date K et al., 2020. Decision making and implementation of the first public sector introduction of typhoid conjugate vaccine—Navi Mumbai, India, 2018. Clin Infect Dis 71: S172S178.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Hoffman SA et al., 2023. Programmatic effectiveness of a pediatric typhoid conjugate vaccine campaign in Navi Mumbai, India. Clin Infect Dis 77: 138144.

  • 16.

    Farrington CP , Manning G , 1990. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med 9: 14471454.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Cornfield J , 1951. A method of estimating comparative rates from clinical data; applications to cancer of the lung, breast, and cervix. J Natl Cancer Inst 11: 12691275.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Rodrigues LC , Smith PG , 1999. Use of the case-control approach in vaccine evaluation: Efficacy and adverse effects. Epidemiol Rev 21: 5672.

  • 19.

    Balasubramanian S , Shah A , Pemde HK , Chatterjee P , Shivananda S , Guduru VK , Soans S , Shastri D , Kumar R , 2018. Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization practices (ACVIP) recommended immunization schedule (2018–19) and update on immunization for children aged 0 through 18 years. Indian Pediatr 55: 10661074.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Mogasale V , Ramani E , Mogasale VV , Park J , 2016. What proportion of Salmonella typhi cases are detected by blood culture? A systematic literature review. Ann Clin Microbiol Antimicrob 15: 32.

    • PubMed
    • Search Google Scholar
    • Export Citation

Author Notes

Financial support: This work was supported by Bill & Melinda Gates Foundation grant OPP1169264 (principal investigator S. P. Luby). C. LeBoa is funded by the Global Health Equity Scholars Program NIH FIC (Award no. D43TW010540). S. A. Hoffman is supported in part by the NIH under the National Institute of Allergy and Infectious Diseases grant T32AI007502, as well as by the Stanford Maternal and Child Health Research Institute. K. Date reports CDC employee—salary through employer.

Disclosure: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position, policies, or views of the U.S. Centers for Disease Control and Prevention or the World Health Organization.

Current contact information: Kashmira Date, Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, and Johnson & Johnson Global Public Health, New Brunswick, NJ, E-mail: kashmira.date@gmail.com. Christopher LeBoa, National Public Health Surveillance Project, Country Office for India, World Health Organization, New Delhi, India, and Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, CA, E-mail: cleboa@berkeley.edu. Seth A. Hoffman, Jason R. Andrews, Stephen P. Luby, Lily Horng and Kirsten Fagerli, Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, E-mails: sethhoffman@stanford.edu. jandr@stanford.edu, sluby@stanford.edu, lily.horng@gmail.com, and kirsten.fagerli@mcri.edu.au. Pradeep Haldar, Ministry of Health & Family Welfare, Government of India, New Delhi, India, E-mail: pradeephaldar@yahoo.co.in. Pauline Harvey, U.S. Centers for Disease Control and Prevention, Atlanta, GA, E-mail: pdh7@cdc.gov. Qian An, Chenhua Zhang, Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, E-mails: fei8@cdc.gov and noi7@cdc.gov. Vijay Yewale and Dhanya Dharmapalan, Dr. Yewale Multispecialty Hospital for Children, Navi Mumbai, India, E-mails: vnyewale@gmail.com and drdhanyaroshan@gmail.com. Savita Daruwalla and Rajesh Rai, Department of Pediatrics, NMMC General Hospital, Navi Mumbai, India, E-mails: childoc62@gmail.com and drrajeshrai@yahoo.com. Jeetendra Gavhane, Department of Pediatrics, MGM New Bombay Hospital, MGM Medical College, Navi Mumbai, India, E-mail: drjeetendra@gmail.com. Shrikrishna Joshi, Dr. Joshi’s Central Clinical Microbiology Laboratory, Navi Mumbai, India, E-mail: skajoshi@yahoo.co.in. Varsha Rathod, Rajmata Jijau Hospital, Airoli (NMMC), Navi Mumbai, India, E-mail: vrmsrjhairoli@gmail.com. Keertana Shetty, Department of Microbiology, Dr. D.Y. Patil Medical College and Hospital, Navi Mumbai, India, E-mail: keertana.shetty@gmail.com. Divyalatha S. Warrier, Department of Pediatrics, Mathadi Trust Hospital, Navi Mumbai, India, E-mail: divyawarrier60@gmail.com. Shalini Yadav, Department of Microbiology, MGM New Bombay Hospital, Navi Mumbai, India, E-mail: doc_shalini@rediffmail.com. Niniya Jayaprasad, India Hypertension Control Initiative, World Health Organization, New Delhi, India, E-mail: niniya.jayaprasad@yahoo.com. Priyanka Borhade, Rahul Shimpi, Arun Katkar, Abhishek Kunwar, Pankaj Bhatnagar, National Public Health Surveillance Project, Country Office for India, World Health Organization, New Delhi, India, E-mails: dm.tcvwho@gmail.com, shimpir@who.int, katkara@who.int, abhishekk@who.int, and bhatnagarp@who.int. Debjit Chakraborty, National Institute of Cholera and Enteric Diseases, Indian Council of Medical Research, Kolkata, India, E-mail: drdebjitepi@gmail.com. Sunil Bahl, South-East Asia Regional Office, World Health Organization, New Delhi, India, E-mail: bahls@who.int. Shanta Dutta, National Institute of Cholera and Enteric Diseases, Indian Council of Medical Research, Kolkata, India, E-mail: drshantadutta@gmail.com.

Address correspondence to Seth A. Hoffman, Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, 300 Pasteur Dr., Lane Bldg. 134, Stanford, CA 94305. E-mail: shoff@stanford.edu
  • Figure 1.

    Flow chart of study design. TCV = typhoid conjugate vaccine.

  • 1.

    GBD 2017 Typhoid and Paratyphoid Collaborators , 2019. The global burden of typhoid and paratyphoid fevers: A systematic analysis for the global burden of disease study 2017. Lancet Infect Dis 19: 369381.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Mogasale VV , Ramani E , Mogasale V , Park JY , Wierzba TF , 2018. Estimating typhoid fever risk associated with lack of access to safe water: A systematic literature review. J Environ Public Health 2018: 9589208.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    World Health Organization , 2019. Typhoid vaccines: WHO position paper, March 2018—Recommendations. Vaccine 37: 214216.

  • 4.

    Tseng KK , Joshi J , Shrivastava S , Klein E , 2020. Estimating the cost of interventions to improve water, sanitation and hygiene in healthcare facilities across India. BMJ Glob Health 5: e003045.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Kim C , Goucher GR , Tadesse BT , Lee W , Abbas K , Kim JH , 2023. Associations of water, sanitation, and hygiene with typhoid fever in case-control studies: A systematic review and meta-analysis. BMC Infect Dis 23: 562.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Qamar FN et al., 2020. Antimicrobial resistance in typhoidal Salmonella: Surveillance for enteric fever in Asia project, 2016–2019. Clin Infect Dis 71: S276S284.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Birkhold M , Mwisongo A , Pollard AJ , Neuzil KM , 2021. Typhoid conjugate vaccines: Advancing the research and public health agendas. J Infect Dis 224: S781s787.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Mohan VK , Varanasi V , Singh A , Pasetti MF , Levine MM , Venkatesan R , Ella KM , 2015. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: A multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clin Infect Dis 61: 393402.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Shakya M et al., 2021. Efficacy of typhoid conjugate vaccine in Nepal: Final results of a phase 3, randomised, controlled trial. Lancet Glob Health 9: e1561e1568.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Qadri F et al., 2021. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: A cluster-randomised trial. Lancet 398: 675684.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Patel PD et al., 2021. Safety and efficacy of a typhoid conjugate vaccine in Malawian children. N Engl J Med 385: 11041115.

  • 12.

    Gavhane J , Yewale V , Weekey P , Dhanya , Warrior D , 2010. Enteric fever in children from Navi Mumbai—Clinical profile, hematological features, sensitivity patterns and response to antimicrobials. Pediatr Infect Dis 2: 59.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Jayaprasad N , Borhade P , LeBoa C , Date K , Joshi S , Shimpi R , Andrews JR , Luby SP , Hoffman SA , 2023. Retrospective review of blood culture-confirmed cases of enteric fever in Navi Mumbai, India: 2014–2018. Am J Trop Med Hyg 109: 571574.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Date K et al., 2020. Decision making and implementation of the first public sector introduction of typhoid conjugate vaccine—Navi Mumbai, India, 2018. Clin Infect Dis 71: S172S178.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Hoffman SA et al., 2023. Programmatic effectiveness of a pediatric typhoid conjugate vaccine campaign in Navi Mumbai, India. Clin Infect Dis 77: 138144.

  • 16.

    Farrington CP , Manning G , 1990. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med 9: 14471454.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Cornfield J , 1951. A method of estimating comparative rates from clinical data; applications to cancer of the lung, breast, and cervix. J Natl Cancer Inst 11: 12691275.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Rodrigues LC , Smith PG , 1999. Use of the case-control approach in vaccine evaluation: Efficacy and adverse effects. Epidemiol Rev 21: 5672.

  • 19.

    Balasubramanian S , Shah A , Pemde HK , Chatterjee P , Shivananda S , Guduru VK , Soans S , Shastri D , Kumar R , 2018. Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization practices (ACVIP) recommended immunization schedule (2018–19) and update on immunization for children aged 0 through 18 years. Indian Pediatr 55: 10661074.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Mogasale V , Ramani E , Mogasale VV , Park J , 2016. What proportion of Salmonella typhi cases are detected by blood culture? A systematic literature review. Ann Clin Microbiol Antimicrob 15: 32.

    • PubMed
    • Search Google Scholar
    • Export Citation
Past two years Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 830 830 247
PDF Downloads 470 470 95
 
 
 
 
Affiliate Membership Banner
 
 
Research for Health Information Banner
 
 
CLOCKSS
 
 
 
Society Publishers Coalition Banner
Save